Krystal Biotech, Inc. (NASDAQ:KRYS) is Soleus Capital Management L.P.’s 5th Largest Position

Soleus Capital Management L.P. boosted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 65.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 358,379 shares of the company’s stock after purchasing an additional 141,400 shares during the period. Krystal Biotech makes up about 3.5% of Soleus Capital Management L.P.’s investment portfolio, making the stock its 5th biggest holding. Soleus Capital Management L.P.’s holdings in Krystal Biotech were worth $56,144,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the stock. Covestor Ltd boosted its position in shares of Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after buying an additional 642 shares during the period. Avanza Fonder AB acquired a new position in Krystal Biotech during the 4th quarter worth approximately $119,000. KBC Group NV lifted its position in Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock worth $147,000 after acquiring an additional 297 shares in the last quarter. Blue Trust Inc. boosted its holdings in Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after acquiring an additional 433 shares during the period. Finally, US Bancorp DE grew its position in Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after acquiring an additional 82 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on KRYS shares. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital reiterated a “buy” rating and issued a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Guggenheim decreased their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, Citigroup lowered their target price on Krystal Biotech from $215.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Buy” and a consensus price target of $211.13.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This represents a 1.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $130.60 on Monday. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of 43.68 and a beta of 0.79. Krystal Biotech, Inc. has a one year low of $127.40 and a one year high of $219.34. The company’s 50-day simple moving average is $166.74 and its 200-day simple moving average is $168.54.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. As a group, research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).